Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function
Phase of Trial: Phase I/II
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Chronic heart failure; Renal impairment
- Focus Therapeutic Use
- 08 Aug 2016 Planned End Date changed from 1 Apr 2017 to 1 Mar 2017.
- 08 Aug 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Mar 2017.
- 18 Dec 2015 Planned End Date changed from 1 Apr 2014 to 1 Apr 2017 as per ClinicalTrials.gov record.